Statin Use and the Risk of Graves' Orbitopathy: A Nationwide Population-Based Cohort Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Statin use significantly lowers the risk of Graves
Area Of Science
- Endocrinology
- Ophthalmology
- Pharmacology
Background
- Graves' orbitopathy (GO) is a common complication of Graves' disease (GD).
- Statin use has shown potential protective effects against GO in Western populations.
- Data on statin efficacy in preventing GO in Asian populations with GD is limited.
Purpose Of The Study
- To investigate the protective effect of statins against GO in Asian patients with GD.
- To analyze the association between statin use and the incidence of GO in a large Asian cohort.
Main Methods
- Nationwide, population-based retrospective cohort study using NHIRD data (2010-2020).
- Inclusion of GD patients aged >40 years.
- Propensity score matching and IPTW analysis to control for confounding factors.
- Kaplan-Meier survival and multivariable Cox regression analyses were performed.
Main Results
- A total of 102,858 patients were analyzed (7,073 statin users, 95,785 nonusers).
- Statin users exhibited a significantly lower risk of GO (adjusted HR: 0.79, p=0.037 post-PS matching; adjusted HR: 0.64, p<0.001 post-IPTW).
- No significant difference in GO risk was observed among users of different statin types or intensities.
Conclusions
- Statin use is associated with a reduced risk of developing GO in Asian GD patients.
- The findings suggest a potential therapeutic role for statins in GO prevention within this population.
- Further research may explore specific statin mechanisms in GO pathogenesis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...